Alumis Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2834 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy - May 30th, 2025 3:23 am
Alumis to Present at the Jefferies Global Healthcare Investor Conference - May 29th, 2025 2:15 pm
Analysts' Revenue Estimates For Alumis Inc. (NASDAQ:ALMS) Are Surging Higher - May 29th, 2025 12:53 pm
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis - May 29th, 2025 5:55 am
Alumis Completes Merger with ACELYRIN - May 21st, 2025 7:10 am
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - May 14th, 2025 2:05 pm
Alumis Stockholders Approve Merger with ACELYRIN - May 13th, 2025 11:00 am
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - May 13th, 2025 11:00 am
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - May 6th, 2025 2:30 pm
Acelyrin urges stockholders to vote for proposed merger with Alumis - May 2nd, 2025 11:45 am
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - May 1st, 2025 11:30 am
Acelyrin should liquidate instead of merging with Alumis, investor says - Apr 29th, 2025 11:22 am
Alumis and ACELYRIN Announce Amended Merger Agreement - Apr 21st, 2025 4:30 am
Insider Buying: Alumis Independent Director Bought US$130k Of Shares - Apr 5th, 2025 6:15 am
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - Apr 4th, 2025 2:34 pm
Alumis and Kaken sign agreement in Japan to develop ESK-001 - Mar 25th, 2025 8:51 am
Sector Update: Health Care Stocks Steady Premarket Tuesday - Mar 25th, 2025 7:07 am
Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug - Mar 25th, 2025 2:28 am
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan - Mar 25th, 2025 12:30 am
Why Alumis Inc. (ALMS) Went Down On Thursday? - Mar 21st, 2025 5:08 am